ENGINEERED CYTOKINES TO TAME INFLAMMATION

A NOVEL APPROACH TO TREATING AUTOIMMUNE DISEASE

OUT OF THE STORM AND INTO THE CALM [平穏]





EXPERIENCED FOUNDING TEAM



JEFFREY A HUBBELL, PHD

Eugene Bell Professor, Tissue Engineering and Deputy Dean for Development

Pritzker School of Molecular Engineering University of Chicago





JUN ISHIHARA, PHD

Lecturer at Imperial College London

Visiting Position Pritzker School of Molecular Engineering, University of Chicago



AKO ISHIHARA, MD, PHD

Co-founder Arrow Immune Postdoctoral Fellow



CARLO PASSERI


Entrepreneur & Biotech Investor





CURRENT TREATMENTS HAVE SERIOUS SIDE EFFECTS

Current Treatments Suppress the Entire Immune System with Negative Side Effects



SIDE EFFECTS


- Liver problems
- Kidney problems
- Severe infections
- Hep. B reactivation

- Severe skin reactions
- Low white blood cells
- Progressive multifocal leukoencephalopathy




HEIOTHERA'S APPROACH IS UNIQUE

HeioThera Leverages the Body's Natural Systems to Calm the Autoimmune Response



Possible remyelination



A NEW APPROACH TO TREATING AUTOIMMUNE DISEASE

HeioThera Targets the Lymph Nodes & Induce Tolerogenic Response

- **Target accumulation in the lymph nodes** throughout the body by approx. 20-fold
- Via interaction with FcRn in the lymph nodes


Combine with anti-inflammatory cytokines to treat specific autoimmune diseases

HeioThera shapes the immune response by tilting it towards <u>tolerance</u>



HEIOTHERA'S PLATFORM POTENTIAL

More Than One Indication, More Than One Cytokine







CARLO@HEIOTHERA.COM

JUN@HEIOTHERA.COM

JEFF@HEIOTHERA.COM